Company: CGC
Filing Date: 2025-02-28
Form Type: 424B5
Source: 0001104659-25-019242
Chunk: 13

Company: Canopy Growth Corp
Filing Date: 2025-02-28
Form: 424B5
Chunk 13
---
 aggregate principal amount of $750 million (the “Credit Facility”) under a term loan

<div align='center'>S-8</div>

TABLE OF CONTENTS

credit agreement entered into by us on March 18, 2021, as amended (the “Credit Agreement”), and the timing and occurrence of the potential $100 million optional prepayment of the Credit Facility in connection with the amendment to the Credit Agreement entered into on August 8, 2024 (the “Optional Prepayment”);

•

expectations regarding the potential success of, and the costs and benefits associated with, our acquisitions, equity investments and dispositions;

•

the grant, renewal and impact of any license or supplemental license to conduct activities with cannabis or any amendments thereof;

•

our international activities, including required regulatory approvals and licensing, anticipated costs and timing, and expected impact;

•

our ability to successfully create and launch brands and further create, launch and scale products in jurisdictions where such products are legal and that we currently operate in;

•

the benefits, viability, safety, efficacy, dosing and social acceptance of cannabis, including CBD and other cannabinoids;

•

our ability to continue as a going concern;

•

our ability to maintain effective internal control over financial reporting;

•

our expected use of the net proceeds of this offering and the Concurrent Canadian Offering, if any;

•

expectations regarding the use of proceeds of equity financings;

•

the legalization of the use of cannabis for medical or adult-use purposes in jurisdictions outside of Canada, the related timing and impact thereof and our intentions to participate in such markets, if and when such use is legalized;

•

our ability to execute on our strategy and the anticipated benefits of such strategy;

•

the ongoing impact of the legalization of additional cannabis product types and forms for adult-use in Canada, including federal, provincial, territorial and municipal regulations pertaining thereto, the related timing and impact thereof and our intentions to participate in such markets;

•

the ongoing impact of developing provincial, state, territorial and municipal regulations pertaining to the sale and distribution of cannabis, the related timing and impact thereof, as well as the restrictions on federally regulated cannabis producers participating in certain retail markets and our intentions to participate in such markets to the extent permissible;

•

the timing and nature of legislative changes in the U.S. regarding the regulation of cannabis including tetrahydrocannabinol;

•

the future performance of our business and operations;

•

our competitive advantages and business strategies;

•

the competitive conditions of the industry;

•

the expected growth in the number of customers using our products;